Dave is newly diagnosed with acromegaly

Dave is 36 and living in Atlanta.* He is a financial advisor, travels a bit, and plays golf. For two years, joint pain, headache, and fatigue interfered with Dave's work and lifestyle.

Diagnosis

Dave was diagnosed with acromegaly in May 2007 after being referred to a neurologist for severe migraines. The neurologist suspected acromegaly after hearing that Dave also had joint pain and fatigue. His insulin-like growth factor level was 750 ng/mL, well above the normal range. When Dave took an oral glucose tolerance test, it failed to push his growth hormone levels below 1.0 ng/mL. An MRI confirmed the diagnosis of acromegaly.

Treatment history

On the MRI, Dave's pituitary tumor was large (>10 mm). He had surgery in August 2007. That reduced the size of the tumor, but did not normalize levels of growth hormone and growth factors. Dave's endocrinologist recommended medical therapy with a somatostatin analog.

Considering Dave's diagnosis and lifestyle, he may be a candidate for Somatuline® Depot (lanreotide) Injection (lanreotide) Injection treatment.

Do any of your patients resemble Dave?

Last year Somatuline® Depot (lanreotide) Injection helped over 6000 patients with acromegaly,2 including three fictional, but typical, patients named Dave (above), Mark, and Karen (below). See if your patients are like:

* Dave is not an actual patient. His profile is based on published data from clinical studies and review articles.

 

Support for patients taking Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is widely available, including through specialty pharmacies and is expected to be covered by most pharmacy benefit plans.2 Learn more about the reimbursement support for patients on Somatuline® Depot (lanreotide) Injection.

 

See how to inject Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is injected in an easy, two-step injection process.1 Learn more about injecting Somatuline® Depot (lanreotide) Injection.

 

Safety and tolerability of Somatuline® Depot (lanreotide) Injection

Somatuline® Depot (lanreotide) Injection is well-tolerated and had a 1.9% discontinuation rate in a 52-week study.1,2 Learn more about the safety and tolerability of Somatuline® Depot (lanreotide) Injection.